Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT07913594Phase 2Not yet recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of zilovertamab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by Olivia Newton-John Cancer Research Institute. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07913594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913594.